All Articles
![Doctor testing patient](/media/original_images/Web_feature_images_7.jpg.360x190_q88_crop_focal_area-611%2C260%2C1222%2C520_size_canvas_upscale_zoom-100.jpg)
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
Among patients undergoing allogeneic HLA-matched HSCT with reduced-intensity conditioning, GVHD-free, relapse-free survival at 1 year was significantly more common among those who received cyclophosphamide–tacrolimus–mycophenolate mofetil.
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor–positive advanced breast cancer are limited.
Oncology Experts Join Together to Provide Best Possible Care for Adolescents and Young Adults with Cancer
The Hematology/Oncology Pharmacy Association (HOPA) has partnered with Stupid Cancer, the leader in young adult cancer advocacy, research, and support, to develop tools for healthcare providers who serve the adolescent and young adult (AYA) patient commun
![Mantle-Cell Lymphoma](/media/original_images/Web_feature_images_6.jpg.360x190_q88_crop_focal_area-611%2C260%2C1222%2C520_size_canvas_upscale_zoom-100.jpg)
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (M
![colonoscopy image](/media/original_images/Copy_of_Mood_Board_Professional_1222__520_px4.png.360x190_q88_crop_focal_area-611%2C260%2C1222%2C520_size_canvas_upscale_zoom-100.png)